Last reviewed · How we verify
The treatment of investigator choice
The treatment of investigator choice is a Small molecule drug developed by LintonPharm Co.,Ltd.. It is currently in Phase 3 development for Metastatic non-small cell lung cancer.
The treatment of investigator choice works by targeting the underlying cause of the disease.
The treatment of investigator choice works by targeting the underlying cause of the disease. Used for Metastatic non-small cell lung cancer.
At a glance
| Generic name | The treatment of investigator choice |
|---|---|
| Sponsor | LintonPharm Co.,Ltd. |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While the exact mechanism is not well understood, it is believed to involve a complex interplay of molecular pathways and cellular responses.
Approved indications
- Metastatic non-small cell lung cancer
Common side effects
- Fatigue
- Nausea
- Diarrhea
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
- Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer (PHASE3)
- Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) (PHASE3)
- MP101 in Adults With Acute Pseudomonas Aeruginosa Pneumonia (PHASE1)
- Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for Serious Gram-negative Infections (PHASE2)
- Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients (PHASE2)
- APLAUD Trial (Antibiotics vs PLacebo for Acute Uncomplicated Diverticulitis) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- The treatment of investigator choice CI brief — competitive landscape report
- The treatment of investigator choice updates RSS · CI watch RSS
- LintonPharm Co.,Ltd. portfolio CI
Frequently asked questions about The treatment of investigator choice
What is The treatment of investigator choice?
How does The treatment of investigator choice work?
What is The treatment of investigator choice used for?
Who makes The treatment of investigator choice?
What development phase is The treatment of investigator choice in?
What are the side effects of The treatment of investigator choice?
Related
- Manufacturer: LintonPharm Co.,Ltd. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic non-small cell lung cancer
- Compare: The treatment of investigator choice vs similar drugs
- Pricing: The treatment of investigator choice cost, discount & access